Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials

Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials

Vaccination plays a key role in preventing morbidity and mortality caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We aimed to evaluate the safety and immunogenicity of a SARS-CoV-2 messenger ribonucleic acid (mRNA) vaccine SYS6006. In the two randomized, observer-blinded...

Full description

Saved in:
Bibliographic Details
Main Authors: Gui-Ling Chen, Yuan-Zheng Qiu, Kai-Qi Wu, Ying Wu, Yuan-Hui Wang, Yu-Ying Zou, Cong-Gao Peng, Jie Zhao, Chang Su, Jun-Heng Ma, Shao-Nan Ni, Xing Wang, Ting-Han Jin, Qi Jiang, Tong Guo, Yan Xu, Chao-Chao Huang, Qing Zhang, Kai-Li Liu, Li Ji, Han-Yu Yang, Chun-Lei Li, Yu-Wen Su, Xiang Lu, Lan-Juan Li
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
SARS-CoV-2
mRNA vaccine
safety
immunogenicity
clinical trial
placebo-controlled
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2023.2285089
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2023.2285089

Similar Items